Knowledge, attitude and practices regarding the use of medical cannabis: A national survey among Israeli oncologists.

Authors

null

Dan Mirelman

Tel Aviv Medical Center, Tel Aviv, Israel

Dan Mirelman , Barliz Waissengrin , Noam Goldway , Hagai Sharon , Silviu Brill , Ido Wolf

Organizations

Tel Aviv Medical Center, Tel Aviv, Israel, Tel Aviv Medical Center and Sackler School of Medicine, Tel Aviv, Israel, Tel Aviv Sourasky medical center, Tel Aviv, Israel

Research Funding

No funding received
None

Background: Despite lack of clinical trials reporting on beneficial effects of the cannabis plant for cancer-associated symptoms, its use is increasing worldwide. Approximately 10,000 Israeli cancer patients receive permits for the use of medical cannabis, making cannabis one of the most commonly prescribed oncology treatments in Israel and making the Israeli oncologists highly experienced with its use. The experience gained by the Israeli oncologists is therefore highly valuable. Methods: We conducted a web-based survey among all 238 Israeli oncologists, addressing personal experience; knowledge and attitudes toward the use of cannabis in oncology. Results: Response rate was 54% (n = 126), with the vast majority (87%) regularly prescribing cannabis to their patients. Anorexia, pain and nausea were the most common indications for cannabis use. While 90% of responders stated lack of sufficient knowledge regarding cannabis, its use was perceived as effective and safe. Interestingly, while most oncologists stated that opioids should be used as a first line treatment for cancer pain, most would prefer cannabis for pain relief if needed by a close relative. Oncologists who support cannabis legalization were more likely to prescribe it. Conclusions: Our findings indicate extensive use and perception of medical cannabis despite lack of knowledge, and support about efficacy and indicate a unique role for moral attitudes affecting clinical decisions. These data call for the implementation of an educational program and practical guidelines enabling more consistent and rational approach toward cannabis role in oncology.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Publication Only

Session Title

Publication Only: Symptoms and Survivorship

Track

Symptom Science and Palliative Care

Sub Track

Palliative Care and Symptom Management

Citation

J Clin Oncol 38: 2020 (suppl; abstr e24125)

DOI

10.1200/JCO.2020.38.15_suppl.e24125

Abstract #

e24125

Abstract Disclosures

Similar Abstracts

First Author: Meghan Beck

First Author: Dan Mirelman

First Author: Desiree Rachel Azizoddin

Abstract

2023 ASCO Annual Meeting

Cannabis use among recently treated cancer patients: Perceptions and experiences.

First Author: Talya Salz